1. Introduction {#sec1-brainsci-08-00194}
===============

Parkinson's disease (PD) is a common and debilitating neurodegenerative disorder. First described in 1817 by James Parkinson, PD is a chronic condition distinguished by bradykinesia, rigidity, postural instability, and resting tremor often described as "pill-rolling." The clinical features are due to the loss of dopaminergic neurones located in the pars compacta of the substantia nigra. Why these neurons are lost is poorly understood. However, numerous studies from animal models and familial cases of PD have identified that accumulation of cytoplasmic inclusions of alpha-synuclein (α-synuclein) called Lewy bodies, oxidative stress, and mitochondrial dysfunction may all play a pathogenic role in their destruction \[[@B1-brainsci-08-00194],[@B2-brainsci-08-00194]\].

Despite multiple well-documented risk factors suggesting an environmental association such as well-water drinking, pesticide exposure, head injury, and rural living \[[@B3-brainsci-08-00194]\], only increased age carries sufficient statistical evidence to be causative \[[@B4-brainsci-08-00194]\]. Male gender and Caucasian ethnicity were reported to increase the risk of PD in research studies while tobacco smoking has been found to be protective. Therefore, the existence of other aetiological mechanisms not yet identified must be considered.

Parkinsonism is a clinical picture of a tremor, rigidity, bradykinesia, and postural instability most frequently caused by sporadic PD. However, it has been described in many other conditions. Parkinsonism can be associated with additional features such as dystonia, early autonomic dysfunction, a rapidly progressive disease course, or levodopa unresponsiveness \[[@B5-brainsci-08-00194]\]. In this instance, it is described as atypical Parkinsonism since it differs from the typical clinical picture seen in Parkinson's disease.

Inborn errors of metabolism (IEMs) are a large collection of individually rare but collectively common inherited conditions \[[@B6-brainsci-08-00194]\]. They are a diverse set of conditions that occur as a result of a monogenic mutation resulting in a deficiency of an enzyme or cofactor \[[@B7-brainsci-08-00194]\]. Metal storage disorders are a large subset of these.

Studies have found that patients with PD have increased levels of iron accumulation in the basal ganglia compared with healthy controls \[[@B8-brainsci-08-00194]\]. Research has also been conducted into the potential toxic mechanisms of iron causing nigral cell death and leading to PD features in sporadic PD patients even though it remains unclear whether neuronal death is a direct result of iron accumulation or if the accumulation is a by-product of dopaminergic cell death \[[@B9-brainsci-08-00194]\].

This systematic review aims to identify whether there is a wider pathological link between PD and metal storage disorders by exploring published accounts of Parkinsonism in patients with a previously diagnosed metal storage disorder. Identifying other conditions that produce Parkinsonian-like clinical features may uncover novel pathological mechanisms that contribute to the development of PD. In addition, this paper will discuss whether the clinical features seen in the patients with metal storage disorders displaying Parkinsonism are of a typical picture seen in PD or if they are more similar to atypical Parkinsonism.

2. Materials and Methods {#sec2-brainsci-08-00194}
========================

This systematic review was conducted by following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 guidance \[[@B10-brainsci-08-00194]\].

2.1. Search Terms {#sec2dot1-brainsci-08-00194}
-----------------

Systematic literature searches were conducted in the PubMed and Ovid SP databases including all published articles prior to the search date. The last search was completed on 6 September, 2018. The titles and abstracts were searched by combining two search terms (Term A and Term B). Term A was 'Parkinson,' 'Parkinson's,' 'Parkinsonism,' or 'Parkinsonian' while Term B included each of the individual metal storage disorders. A list of metal storage disorders was collated from a relevant review article \[[@B11-brainsci-08-00194]\]. A full list of the search terms can be found in [Appendix A](#app1-brainsci-08-00194){ref-type="app"}.

2.2. Inclusion Criteria {#sec2dot2-brainsci-08-00194}
-----------------------

Human studies of all designs were considered except review articles. Only publications describing patients with a definite genomic or biochemical diagnosis of a metal storage disorder were analysed. Publications reporting adults, children, and infants were all included since metal storage disorders and Parkinsonian features can present at any age. Cohorts from all nationalities and ethnic backgrounds were also included.

2.3. Exclusion Criteria {#sec2dot3-brainsci-08-00194}
-----------------------

Animal and cellular model studies were excluded as well as autopsy reports. Papers describing PD patients with MSD associated gene mutations were also excluded unless they had a confirmed diagnosis of that disorder. Publications written in languages other than English, without whole text translations available, were excluded. Reviews and letters to editors were also excluded but the references examined to identify any potentially relevant references that the searches had omitted were accepted.

2.4. Selection Process {#sec2dot4-brainsci-08-00194}
----------------------

The publications acquired from the searches were screened in line with the selection criteria by reading the titles and abstracts to assess relevance. Afterward, full texts were sought for all papers eligible for inclusion. Two reviewers conducted this screening process to ensure adherence to selection criteria. Conflicts were resolved through discussion between the reviewers.

2.5. Data Extraction {#sec2dot5-brainsci-08-00194}
--------------------

The primary outcomes extracted from the publications were the type of study, the IEM affecting the patients reported in the study, and whether the patient had features of typical or atypical Parkinsonism. Patients were identified as possessing atypical Parkinsonism if there was evidence of early autonomic dysfunction, a rapidly progressive course, lack of asymmetrical features at onset, and a poor response to conventional levodopa therapy or a Parkinson-Plus syndrome, as per the definition in the introduction. Where available, the gender, age of onset of Parkinsonian features, smoking status, and ethnicity were recorded as secondary outcomes. A breakdown of the data collected from each individual paper including the clinical picture of the patients can be found in [Table A1](#brainsci-08-00194-t0A1){ref-type="table"}.

3. Results {#sec3-brainsci-08-00194}
==========

In total, 967 publications were identified corresponding to 827 unique articles which underwent the screening process. Following the title and abstract review, 730 were excluded since they did not satisfy the inclusion criteria. Following full text screening, a further 53 records were excluded. Six additional relevant publications were identified from hand searching the reference lists of the reviews and letters identified in the searches. A total of 50 papers were included in this review. [Figure 1](#brainsci-08-00194-f001){ref-type="fig"} shows a PRISMA flowchart of the selection process. The final group of articles consisted of 40 (80.0%) case reports and series, nine (18.0%) cross-sectional studies, and one (2.0%) cohort study ([Table 1](#brainsci-08-00194-t001){ref-type="table"}). The year of publications ranged from 1981 to 2018 with three (6.0%) papers published before 1990, three (6.0%) papers published in the decade between 1991 to 2000, 12 (24.0%) papers published from 2001 to 2010, and 32 (64.0%) papers published in the current decade from 2011 to 2018 ([Table 1](#brainsci-08-00194-t001){ref-type="table"}).

Typical Parkinsonism was reported in 16 (32.0%) publications and atypical in 38 (76.0%) publications, which is shown in [Table 2](#brainsci-08-00194-t002){ref-type="table"}. Of these papers, four described subjects with both typical and atypical features. Additionally, 173 patients were reported to have Parkinsonism, 86 (49.7%) were male, and the average age of onset was 35 years old. The ratio of males to females observed was 0.99:1 (86 males to 87 females). The smoking status was not reported in any of the publications ([Appendix B](#app2-brainsci-08-00194){ref-type="app"}).

Pantothenate kinase-associated neurodegeneration (PKAN), which is the most prevalent neurodegenerative brain iron accumulation (NBIA) disorder, was the most documented metal storage disorder and was reported in 11 papers. All of these publications described patients displaying features of atypical Parkinsonism. Three papers also described subjects with typical Parkinsonian features. Within the 85 PKAN patients reflected by these articles, the mean age of onset of Parkinsonism was 33 years old. The gender ratio was 1.36:1 with 49 males and 36 females described. PLA2G6-associated neurodegeneration (PLAN) was another frequently identified NBIA with three publications identified. Typical parkinsonism features were described by two of these papers while the remaining publications reported atypical Parkinsonism. Other NBIAs identified beta-propeller protein-associated neurodegeneration (BPAN) with five publications (four with atypical Parkinsonism and one with typical features), Kufor-Rakeb Syndrome with five articles (all atypical, although one described patients with typical features), and mitochondrial-membrane protein-associated neurodegeneration (MPAN) (three papers describing atypical parkinsonism). In addition, three publications described atypical features in subjects with neuroferritinopathy and one paper described a patient with Aceruloplasminemia presenting with features of atypical Parkinsonism. An additional paper described a subject with atypical features who suffered from an unknown type of NBIA.

After PKAN and NBIAs, the next most reported metal storage disorders were Hereditary Haemochromatosis (HH) and Wilson's disease. Seven articles were identified that reported patients with HH and four papers (57.1%) described typical Parkinsonism. In these publications, 14 subjects were described including 10 males and 4 females (a ratio of 2.5:1). The mean age of onset of Parkinsonism in these patients was calculated at 53 years of age. Parkinsonism in Wilson's disease patients was reported in six papers in which four (66.6%) described typical features while the remaining two papers (33.3%) displayed atypical pictures. The mean age of onset in the patients described was 46 years of age and a gender ratio 0.75:1 (three males and six females).

4. Discussion {#sec4-brainsci-08-00194}
=============

Parkinsonian presentation in patients with metal storage disorders is an area of growing interest. The number of publications identified in this study increases each decade. While only three articles were published earlier than 1990, between the years 2010 to 2018, 29 papers were identified. This demonstrates an increasing amount of research being conducted in this field and a growing appreciation for a possible correlation between Parkinsonism and metal storage disorders.

The family of neurodegenerative brain iron accumulation (NBIA) disorders includes Pantothenate kinase-associated neurodegeneration (PKAN), Aceruloplasminemia, beta-propeller protein-associated neurodegeneration (BPAN), Kufor-Rakeb Syndrome, mitochondrial-membrane protein-associated neurodegeneration (MPAN), neuroferritinopathy, and PLA2G6-associated neurodegeneration (PLAN). Articles discussing all of these disorders were identified by our searches and described patients displaying Parkinsonism. These all showed a similar phenotype with young average ages of onset of Parkinsonism ranging from 13 years old (Kufor-Rakeb syndrome) to 61 years old (neuroferritinopathy) and predominantly atypical Parkinsonian features. This reflects the similar pathologies across the NBIA family of disorders. In all NBIAs, increased deposition of iron in brain tissue is observed. It is unclear whether this deposition is the direct cause of neurodegeneration or if it is simply a marker of the degeneration occurring as a result of some other pathological mechanism. However, Parkinsonism as well as dystonia appears well documented across all NBIAs.

In line with our findings, PKAN is the most common NBIA accounting for roughly half of all cases \[[@B12-brainsci-08-00194]\]. In the 11 publications describing PKAN, all papers described patients with atypical features while three also described patients with typical Parkinsonism. The atypical features displayed in these patients were a poor levodopa response \[[@B13-brainsci-08-00194],[@B14-brainsci-08-00194],[@B15-brainsci-08-00194],[@B16-brainsci-08-00194]\], a lack of asymmetrical features \[[@B15-brainsci-08-00194],[@B17-brainsci-08-00194],[@B18-brainsci-08-00194],[@B19-brainsci-08-00194]\], or the presence of dystonia in addition to Parkinsonism \[[@B14-brainsci-08-00194],[@B20-brainsci-08-00194],[@B21-brainsci-08-00194],[@B22-brainsci-08-00194]\] ([Appendix B](#app2-brainsci-08-00194){ref-type="app"}). In two publications, pyramidal signs were also observed \[[@B19-brainsci-08-00194],[@B23-brainsci-08-00194]\]. Recent research has established that Lewy body pathology is not observed in PKAN, which may explain why atypical features of Parkinsonism are more commonly seen \[[@B24-brainsci-08-00194]\]. Historical reports of patients with PKAN have found α-synuclein inclusions in neurons \[[@B7-brainsci-08-00194],[@B25-brainsci-08-00194]\]. However, Schneider et al. believe these patients may have been misdiagnosed since these reports were published before gene identification was available for diagnosing PKAN \[[@B24-brainsci-08-00194]\]. They describe a recent series of genetically confirmed PKAN patients in which all lacked any evidence of Lewy body pathology. This suggests a differing pathology is occurring in these patients. Our results showing a high prevalence of atypical Parkinsonism in PKAN sufferers supports this hypothesis. At the same time, the widespread presence of α-synuclein inclusions in the central nervous system (CNS) tissue of PLAN patients is well documented \[[@B26-brainsci-08-00194],[@B27-brainsci-08-00194]\], which indicates a potential pathological link between PLAN and sporadic PD. The results from this review support this link with two of the three publications describing patients with PLAN due to features of typical Parkinsonism \[[@B28-brainsci-08-00194],[@B29-brainsci-08-00194]\]. In the one paper describing atypical parkinsonism features in patients with PLAN, dystonia was present \[[@B30-brainsci-08-00194]\].

Hereditary haemochromatosis (HH) was also frequently identified in this systematic review. Four papers reported typical Parkinsonism \[[@B31-brainsci-08-00194],[@B32-brainsci-08-00194],[@B33-brainsci-08-00194],[@B34-brainsci-08-00194]\] while atypical features were described in the remaining three papers. All papers were related to unresponsiveness to levodopa \[[@B35-brainsci-08-00194],[@B36-brainsci-08-00194],[@B37-brainsci-08-00194]\]. These reports of Parkinsonism and HH presenting concurrently indicate that research into iron accumulation in the CNS tissue of HH patients may clarify the pathological link between HH and PD. The pathological processes and brain regions involved in HH are not well understood. In particular, the location of iron accumulation in CNS tissue is poorly documented. Since Parkinson's disease treatments were reported to be ineffective in these patients and an atypical picture was observed, it may be that a different area of the brain is affected. Further research is required in order to identify how and where the iron accumulation occurs in order to draw further conclusions from this result.

Six publications described Parkinsonism in Wilson's disease. It is well established that copper deposition, as seen in Wilson's disease patients, commonly has toxic effects in the brain, which leads to severe neurological features \[[@B38-brainsci-08-00194],[@B39-brainsci-08-00194]\]. How copper causes neuronal death is not well understood even though it is generally accepted that the copper accumulates extracellularly and does not enter neurons \[[@B38-brainsci-08-00194]\]. Within this group, four publications described typical Parkinsonism in Wilson's disease \[[@B40-brainsci-08-00194],[@B41-brainsci-08-00194],[@B42-brainsci-08-00194],[@B43-brainsci-08-00194]\] and two described atypical parkinsonism \[[@B44-brainsci-08-00194],[@B45-brainsci-08-00194]\]. Although Parkinsonism is a common feature of neurologic Wilson's disease \[[@B38-brainsci-08-00194],[@B39-brainsci-08-00194]\], there is no evidence to suggest that Wilson's disease causes Lewy body pathology. Despite this, all of the Wilson's Disease patients from this study displayed levodopa responsiveness. This included two patients with atypical parkinsonism where one had dystonia \[[@B44-brainsci-08-00194]\] and one had epilepsy \[[@B45-brainsci-08-00194]\]. As mitochondrial dysfunction plays a large role in the pathophysiology of PD \[[@B1-brainsci-08-00194],[@B2-brainsci-08-00194]\], the extracellular accumulation of copper in the CNS may have the same effect on mitochondria within the neuron that it does within the hepatocytes. Despite the similarities in clinical features and the response to levodopa, these patients' demographics differ significantly to those seen in the sporadic PD population, which is outlined by Rizek et al. \[[@B46-brainsci-08-00194]\]. The average age of onset of Parkinsonism in these Wilson's disease patients was reported as 46 years old, which is considerably younger than in the sporadic PD population (mean age 65 years old). Furthermore, twice as many females as males were described as having Parkinsonism, which differs greatly to the ratio of 1.5 males per females seen in the sporadic PD population. However, since only nine patients were described, this is not a large enough population to draw generalizable conclusions especially since the lack of α-synuclein pathology indicates the presence of a different pathological process.

Despite previous research establishing that cigarette smoking is protective for PD \[[@B4-brainsci-08-00194]\], the smoking status was not reported in any of the publications ([Appendix B](#app2-brainsci-08-00194){ref-type="app"}). Therefore, it was not possible to investigate this in the current study. It would be pertinent to include the smoking status in the patient demographics of all future publications describing PD or features of Parkinsonism.

The precise nature of the relationship between iron accumulation in patients with Parkinsonism is not clear. Autopsy studies were excluded from this review since they offered retrospective details of the clinical picture and the timelines were poorly outlined. However, they could yield some useful findings in patients with metal storage disorders. Post mortem brain studies on patients with NBIAs allows us to investigate the correlation between the quantity of iron and the severity of PD features. Should this confirm that iron accumulation in the brain leads to the development of Parkinsonism, it follows that treatments to reduce the CNS iron levels, or act as an iron chelator, could be developed as an early treatment for patients with sporadic PD in order to delay the Parkinsonian features.

An important factor to consider when interpreting these results is the level and quality of evidence available in the literature. The majority of the publications included were case reports and case series that the Oxford Centre of Evidence-Based Medicine considers level 4 evidence \[[@B47-brainsci-08-00194]\]. However, due to the rarity of these individual IEMs, this was the highest level of evidence available. Case reports can be subject to bias and, although no formal bias assessment was conducted, a more favourable response to levodopa or exaggeration of the severity of the features may have been reported. This was taken into consideration when evaluating articles for inclusion and any paper describing a response less than moderate to levodopa was classed as atypical.

5. Conclusions {#sec5-brainsci-08-00194}
==============

In conclusion, the presence of Parkinsonism in metal storage disorders is an under reported topic. Establishing the relationships between these conditions may clarify the pathological mechanisms of Parkinsonism. Therefore, it is a field of growing interest with the number of publications describing patients with metal storage disorders displaying Parkinsonism growing substantially each decade. This review has demonstrated the following:There is evidence of Parkinsonism coexisting with metal storage disorders in particular neurodegenerative brain iron accumulation disorders.Patients with these metal storage disorders have an earlier age of onset of Parkinsonism than sporadic PD patients, which suggests additional underlying pathological processes are taking place. The ratio of males to females seen in many of these also differs significantly to the sporadic PD population, which further indicates a differing pathogenesis.Future research must be conducted at a higher level than individual case reports to better assess the relationship between metal storage disorders and Parkinsonism. Cohort studies or case control studies using large cohorts will lead to a reliable dataset. At the same time, research in sporadic PD patients will identify whether any of the pathological mutations or processes are involved in the disorders discussed in relation to the development of Parkinsonism.Smoking status and ethnicity should be documented in all future studies of Parkinsonism since Caucasian ethnicity is a large risk factor in sporadic PD while cigarette smoking appears to be protective. Recording these demographics will allow for the investigation of their presence in patients with metal storage disorders.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Paper                                                                              Type of Paper           Condition                     Male/Female   Average Age at Onset of Parkinsonism (years)   Ethnicity                          Smoking Status   Typical Parkinsonism   Atypical Parkinsonism   Parkinsonism Features
  ---------------------------------------------------------------------------------- ----------------------- ----------------------------- ------------- ---------------------------------------------- ---------------------------------- ---------------- ---------------------- ----------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Alberca, R. et al., 1987. \[[@B20-brainsci-08-00194]\]                             Case report             PKAN                          1M/1F         27                                             NA                                 NA               ✓                      ✓                       Female siblings: Typical features. Male sibling: associated with dystonia.\
                                                                                                                                                                                                                                                                                                           Fast progression.

  Batla, A. et al., 015. \[[@B48-brainsci-08-00194]\]                                Case report             Neuroferritinopathy           1F            79                                             NA                                 NA                                      ✓                       Associated with dystonia.

  Behrens, M.I. et al., 2010. \[[@B49-brainsci-08-00194]\]                           Case Series             Kufor-Rakeb Syndrome          4M/1F         NA                                             Chilean                            NA                                      ✓                       Parkinsonian features in all five pts. No tremor present. Supranuclear gaze palsy in 4/5, poor L-dopa response

  Bozi, M. et al.,\                                                                  Case report             PKAN                          1M            15                                             NA                                 NA                                      ✓                       Mildly affected but associated with pyramidal signs.
  2009. \[[@B23-brainsci-08-00194]\]                                                                                                                                                                                                                                                                       

  Chinnery, P.F. et al., 2007. \[[@B50-brainsci-08-00194]\]                          Cross-sectional study   Neuroferritinopathy           3F            NA                                             2 English,\                        NA                                      ✓                       Associated with dystonia in all three.\
                                                                                                                                                                                                        1 French                                                                                           No tremor present.

  Costello, D.J. et al., 2004. \[[@B31-brainsci-08-00194]\]                          Case report             Hereditary Haemochromatosis   3M/1F         53                                             NA                                 NA               ✓                                              Four pts all with HH and IPD diagnoses, classical signs. Good L-dopa response.

  Crosiers, D. et al., 2011. \[[@B51-brainsci-08-00194]\]                            case report             Kufor-Rakeb syndrome          1M            10                                             Afghan                             NA                                      ✓                       Associated with dystonia.

  Czlonkowska, A. et al., 2018. \[[@B40-brainsci-08-00194]\]                         Cross-sectional study   Wilson's disease              NA            NA                                             Polish                             NA               ✓                                              Parkinsonism found in 11.3% (6/53 pts).

  Darling, A. et al., 2017. \[[@B21-brainsci-08-00194]\]                             Cross-sectional study   PKAN                          22M/25F       NA                                             NA                                 NA                                      ✓                       Features of Parkinsonism displayed in all 47 pts. Associated with Dystonia.

  Demarquay, G. et al., 2000. \[[@B35-brainsci-08-00194]\]                           Case report             Hereditary Haemochromatosis   2M/1F         56                                             NA                                 NA                                      ✓                       Bradykinesia and rigidity on left side. Poor L-dopa response.

  Di Fonzo, A. et al., 2007. \[[@B52-brainsci-08-00194]\]                            Cross-sectional study   Kufor-Rakeb Syndrome          3M            NA                                             NA                                 NA               ✓                      ✓                       Features of Parkinsonism in all three pts. Supranuclear gaze palsy and hallucinations/psychotic episodes in 1/3, psychotic episodes in 1/3, and typical features in 1/3.

  Diaz, N., 2013. \[[@B13-brainsci-08-00194]\]                                       Case report             PKAN                          1F            NA                                             NA                                 NA                                      ✓                       L-dopa unresponsive, symmetrical features.

  Eiberg, H. et al., 2012. \[[@B53-brainsci-08-00194]\]                              Case report             Kufor-Rakeb Syndrome          1M            12                                             NA                                 NA                                      ✓                       Supranuclear gaze palsy, cognitive impairment, and hallucinations.

  Evans, B.K. & Donley, D.K., 1988. \[[@B54-brainsci-08-00194]\]                     Case report             Pseudohypoparathyroidism      1F            20                                             NA                                 NA                                      ✓                       Rest tremor and bradykinesia with mental retardation.

  Fekete, R., 2012. \[[@B55-brainsci-08-00194]\]                                     Case report             NBIA, unknown type            1M            73                                             NA                                 NA                                      ✓                       Typical features. Poor L-dopa response but dystonia present upon removal of L-dopa.

  Fonderico, M. et al., 2017. \[[@B56-brainsci-08-00194]\]                           Case report             BPAN                          1F            26                                             NA                                 NA               ✓                                              Mild typical parkinsonism.

  Gasca-Salas, C. et al., 2017. \[[@B44-brainsci-08-00194]\]                         Case report             Wilson's Disease              1F            38                                             NA                                 NA                                      ✓                       Tremor, clumsiness, rigidity, and dystonia in left arm. Good L-dopa response.

  Giri, A. et al., 2016. \[[@B28-brainsci-08-00194]\]                                Case report             PLAN                          1F            27                                             NA                                 NA               ✓                                              Typical Features, PD diagnosis.

  Girotra, T., Mahajan, A. & Sidiropoulos, C., 2017. \[[@B32-brainsci-08-00194]\]    Case report             Hereditary Haemochromatosis   1M            41                                             Caucasian                          NA               ✓                                              Typical features, mild but clear response to L-dopa.

  Gondim, F. de A.A. et al., 2014. \[[@B41-brainsci-08-00194]\]                      Case Series             Wilson's disease              2M/2F         28                                             Brazil                             NA               ✓                                              Four pts with typical features, all responded well to L-dopa.

  Gore, E. et al., 2016. \[[@B57-brainsci-08-00194]\]                                Case report             MPAN                          1M            35                                             Kuwaiti                            NA                                      ✓                       Early behavioural change.

  Hayflick, S.J. et al., 2013. \[[@B58-brainsci-08-00194]\]                          Cohort study            BPAN                          3M/18F        25                                             NA                                 NA                                      ✓                       Developmental delay, dystonia, and parkinsonism. L-dopa responsive.

  Hermann, A. et al., 2017. \[[@B59-brainsci-08-00194]\]                             Case report             BPAN                          1F            24                                             German                             NA                                      ✓                       Supranuclear gaze palsy, dystonia, and no L-dopa response.

  Ichinose, Y. et al., 2014. \[[@B60-brainsci-08-00194]\]                            Case report             BPAN                          1F            30                                             NA                                 NA                                      ✓                       Associated with dystonia.

  Kim, Y.J. et al.,\                                                                 Case Series             PLAN                          1M/1F         14                                             Korean                             NA                                      ✓                       Associated with dystonia in 2/2 pts.
  2015. \[[@B30-brainsci-08-00194]\]                                                                                                                                                                                                                                                                       

  Klysz, B., Skowronska, M. & Kmiec, T., 2014. \[[@B61-brainsci-08-00194]\]          Case report             MPAN                          1F            15                                             NA                                 NA                                      ✓                       Chorea, dystonia, and psychological manifestations.

  Kumar, N. et al., 2016. \[[@B33-brainsci-08-00194]\]                               Case Series             Hereditary Haemochromatosis   2M/1F         59                                             1 Irish-Portuguese, 1 Scottish,\   NA               ✓                                              Parkinsonian signs in three pts. One responded well to L-dopa, one not treated.
                                                                                                                                                                                                        1 unknown                                                                                          

  Lee, C.-H. et al., 2013. \[[@B17-brainsci-08-00194]\]                              Case report             PKAN                          2M            20                                             Taiwanese                          NA               ✓                      ✓                       Typical parkinsonism in one pt though onset at 18. Bilateral features in the other.

  Lee, J.-H. et al., 2016. \[[@B14-brainsci-08-00194]\]                              Cross-sectional study   PKAN                          6M            36                                             NA                                 NA                                      ✓                       Poor response to L-dopa in all. Associated with dystonia in 4/6 pts, isolated parkinsonism in 2/6 pts.

  Mak, C.M. et al., 2011. \[[@B18-brainsci-08-00194]\]                               Case report             PKAN                          1M            27                                             Hong Kong                          NA                                      ✓                       Bilateral features.

  Ni, W. et al., 2016. \[[@B62-brainsci-08-00194]\]                                  Case report             Neuroferritinopathy           1F            44                                             NA                                 NA                                      ✓                       No response to L-dopa, pyramidal signs.

  Nielsen, J.E., Jensen, L.N. & Krabbe, K., 1995. \[[@B34-brainsci-08-00194]\]       Case report             Hereditary Haemochromatosis   1M            29                                             NA                                 NA               ✓                                              Typical PD features, immediate improvement with L-dopa.

  Nishioka, K. et al., 2015. \[[@B63-brainsci-08-00194]\]                            Cross-sectional study   BPAN                          7F            32                                             NA                                 NA                                      ✓                       Cognitive dysfunction as presenting symptom in all seven. Otherwise typical parkinsonism. L-dopa responsive.

  Oder, W. et al.,\                                                                  Cross-sectional study   Wilson's Disease              NA            NA                                             NA                                 NA               ✓                                              8/25 pts with parkinsonian features. Bradykinesia, resting tremor present.
  1991. \[[@B42-brainsci-08-00194]\]                                                                                                                                                                                                                                                                       

  Olgiati, S. et al.,\                                                               Cross-sectional study   MPAN                          NA            NA                                             NA                                 NA                                      ✓                       9/15 pts with parkinsonian features. Cognitive impairment and pyramidal signs seen.
  2017. \[[@B64-brainsci-08-00194]\]                                                                                                                                                                                                                                                                       

  Pearson, D.W. et al., 1981. \[[@B65-brainsci-08-00194]\]                           Case report             Pseudohypoparathyroidism      1M            58                                             NA                                 NA                                      ✓                       Typical PD features. Very fast disease progression.

  Pestana Knight, E.M., Gilman, S. & Selwa, L., 2009. \[[@B45-brainsci-08-00194]\]   Case report             Wilson's Disease              1M            55                                             NA                                 NA                                      ✓                       Typical PD features associated with epilepsy.

  Racette, B.A. et al., 2001. \[[@B15-brainsci-08-00194]\]                           Case report             PKAN                          1F            60                                             NA                                 NA                                      ✓                       Bilateral features, no response to L-dopa.

  Rohani, M. et al., 2017. \[[@B66-brainsci-08-00194]\]                              Case report             Fahr disease                  1F            50                                             NA                                 NA               ✓                                              Typical L-dopa responsive parkinsonism.

  Rosana, A. & La Rosa, L., 2007. \[[@B36-brainsci-08-00194]\]                       Case report             Hereditary Haemochromatosis   1M            58                                             NA                                 NA                                      ✓                       No response to L-dopa.

  Sakarya, A., Oncu, B. & Elibol, B., 2012. \[[@B19-brainsci-08-00194]\]             Case report             PKAN                          1M            16                                             NA                                 NA                                      ✓                       Early severe cognitive impairment, bilateral onset, pyramidal features.

  Scale, T. et al.,\                                                                 Case report             Fahr Disease                  1M            62                                             NA                                 NA                                      ✓                       No response to L-dopa.
  2014. \[[@B67-brainsci-08-00194]\]                                                                                                                                                                                                                                                                       

  Schneider, S.A. et al., 2010. \[[@B12-brainsci-08-00194]\]                         Case report             Kufor-Rakeb syndrome          1M            16                                             Pakistan                           NA                                      ✓                       Associated with dystonia.

  Sechi, G. et al., 2007. \[[@B43-brainsci-08-00194]\]                               Case report             Wilson's disease              3F            70                                             NA                                 NA               ✓                                              Very late onset L-dopa responsive parkinsonism.

  Seo, J.-H., Song, S.-K. & Lee, P.H., 2009. \[[@B16-brainsci-08-00194]\]            Case report             PKAN                          1M            35                                             NA                                 NA                                      ✓                       No response to L-dopa.

  Song, C.-Y. et al., 2017. \[[@B68-brainsci-08-00194]\]                             Case report             Pseudohypoparathyroidism      1F            52                                             NA                                 NA                                      ✓                       Very fast disease progression.

  Thomas, M., Hayflick, S.J. & Jankovic, J., 2004. \[[@B22-brainsci-08-00194]\]      Cross-sectional study   PKAN                          14M/8F        35                                             NA                                 NA               ✓                      ✓                       Typical parkinsonism seen, though clinical features not defined. Associated with dystonia in 4/22 pts.

  Vroegindeweij, L.H.P. et al., 2017. \[[@B69-brainsci-08-00194]\]                   Case Series             Aceruloplasminemia            4M/1F         NA                                             4 Dutch, 1 Italian                 NA                                      ✓                       Parkinsonian features in all pts. Associated with cognitive decline and cerebellar features in all pts.

  Williams, S. et al., 2013. \[[@B37-brainsci-08-00194]\]                            Case report             Hereditary Haemochromatosis   1F            60                                             Caucasian                          NA                                      ✓                       Short disease course, early autonomic involvement, no L-dopa response.

  Xie, F. et al., 2015. \[[@B29-brainsci-08-00194]\]                                 Case report             PLAN                          2M            34                                             NA                                 NA               ✓                                              Typical features, good L-dopa response.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

![Prisma flow chart illustrating the search strategy and the selection process.](brainsci-08-00194-g001){#brainsci-08-00194-f001}
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###### 

Characteristics of included publications.

  Year of Publication Range               1981--2018
  --------------------------------------- ------------
  **Number of Publications per Decade**   
  Before 1990                             3
  1991--2000                              3
  2001--2010                              12
  2011--2018                              32
  **Type of Study**                       
  Cohort study                            1
  Cross-sectional study                   9
  Case reports/series                     40

brainsci-08-00194-t002_Table 2

###### 

Characteristics of the disorder-related parkinsonism described in the included publications, in order of the number of papers identified.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Condition                                                            Metal Involved   Brain Region Implicated                        Total No. of Papers (No. Typical, No. Atypical)   No. (% Total) of Male and Female Patients Described   Average Age of Patients (Years, Mean ± Standard Error)
  -------------------------------------------------------------------- ---------------- ---------------------------------------------- ------------------------------------------------- ----------------------------------------------------- --------------------------------------------------------
  Panthonase Kinase associated Neurodegeneration (PKAN)                Iron             Basal ganglia (GP, SN)                         11 (3;11)                                         49 M (57.6%)\                                         33 ± 3.8
                                                                                                                                                                                         36 F (42.4%)                                          

  Hereditary Haemochromatosis                                          Iron             \-                                             7 (4;3)                                           10 M (71.4%)\                                         53 ± 3.3
                                                                                                                                                                                         4 F (28.6%)                                           

  Wilson's Disease                                                     Copper           Basal ganglia (PMN, GP)                        6 (6;4)                                           3 M (33.3%)\                                          46 ± 6.8
                                                                                                                                                                                         6 F (66.6%)                                           

  Beta-Propeller Protein-Associated Neurodegeneration (BPAN)           Iron             Basal ganglia (SN, GP)                         5 (1,4)                                           3 M (9.7%)\                                           27 ± 1.1
                                                                                                                                                                                         28 F (90.3%)                                          

  Kufor-Rakeb Syndrome                                                 Iron             Basal Ganglia (SN, GP)                         5 (1;5)                                           10 M (90.9%)\                                         13 ± 0.7
                                                                                                                                                                                         1 F (9.1%)                                            

  Mitochondrial-Membrane Protein-Associated Neurodegeneration (MPAN)   Iron             Basal Ganglia (SN, GP)                         3 (0;3)                                           1 M (50.0%)\                                          25 ± 10.0
                                                                                                                                                                                         1 F (50.0%)                                           

  Neuroferritinopathy                                                  Iron             Cerebellum, Basal ganglia, motor cortex        3 (0;3)                                           5 F (100.0%)                                          61± 17.5

  PLA2G6-Associated Neurodegeneration (PLAN)                           Iron             Basal ganglia (SN, GP)                         3 (2;1)                                           3 M (60.0%)\                                          24 ± 5.2
                                                                                                                                                                                         2 F (40.0%)                                           

  Pseudohypoparathyroidism                                             Calcium          Basal ganglia, deep white matter               3 (0;3)                                           1 M (33.3%)\                                          43 ± 11.8
                                                                                                                                                                                         2 F (66.6%)                                           

  Fahr Disease                                                         Calcium          Basal ganglia, deep white matter, cerebellum   2 (1;1)                                           1 M (50.0%)\                                          56 ± 6.0
                                                                                                                                                                                         1 F (50.0%)                                           

  Aceruloplasminemia                                                   Iron             Basal ganglia                                  1 (0;1)                                           4 M (80.0%)\                                          NA
                                                                                                                                                                                         1 F (20.0%)                                           

  Neurodegenerative Brain Iron Accumulation (NBIA), Unknown Type       Iron             \-                                             1 (0;1)                                           1 M (100.0%)                                          73 ± 0.0

  **Total**                                                            \-               \-                                             50 (16;38)                                        86 M (49.7%)\                                         35 ± 1.6
                                                                                                                                                                                         87 F (50.3%)                                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GP = Globus Pallidus, F = Female, M = Male, PMN = Putamen, SN = Substantia Nigra, NA = Not Available.
